Answers are grounded in this paper and cite their sources.
Understanding the relationship between biomarkers and clinical outcomes is essential in medical research. Although regression models are used to quantify these associations, translating statistical findings into clinical practice remains challenging. Standard practice often reduces assessment to a p-value threshold, labelling a biomarker an ‘independent’ predictor if it passes. This oversimplification obscures nuanced interactions: different modelling strategies can yield divergent interpretations, and results may misrepresent clinical relevance. Large studies may highlight statistically significant but clinically trivial biomarkers, while smaller studies may miss important predictors due to limited power. Moreover, regression coefficients – especially from nonlinear models – often fail to convey the magnitude of association in a clinically intuitive way. Using trial data, our paper examines these limitations and reframes association analysis as a step towards addressing clinical questions: When, and to what extent, does a biomarker improve outcome prediction? We propose that an incremental predictability measure provides a more clinically relevant and interpretable way to quantify biomarker–outcome associations. Our findings underscore the need for analytic approaches that move beyond statistical significance towards measures that reflect clinical value. By emphasizing predictive performance, we aim to improve the translation of statistical associations into actionable insights and support more accurate identification of biomarkers that matter for patient outcomes.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: